CEL-SCI

🇺🇸United States

Introduction: CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts

Phase 1

Terminated

Locations: 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

Phase 3

Completed

Conditions: Squamous Cell Carcinoma of the Oral Cavity
Squamous Cell Carcinoma of the Soft Palate

Interventions: Biological: LI
Drug: Cyclophosphamide
Drug: Indomethacin
Dietary Supplement: Zinc
Procedure: Surgery
Drug: Cisplatin
Radiation: Radiotherapy

Locations: 🇨🇳
Linkou Branch Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan
🇮🇳
Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India
🇨🇦
St. Josephs Healthcare Department of Surgery, Hamilton, Ontario, Canada